The Northern Hospital
Epping, Victoria VIC 3076
1 studies enrolling now · 15 studies all time
What they study most
AML, Adult, Bradycardia, Breast Cancer, Cardiomyopathies, Cardiovascular Disease, Cardiovascular Diseases, Celiac Disease, Coronary Artery Disease (CAD), Critical Illness, Crohn's Disease, Diabetes Mellitus, Type 2, Enteral Feeding Intolerance
Studies at this site
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
- A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease — Stopped early
- PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
- Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet — Completed
- Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia — Completed
- Physiologic Pacing Registry — Completed
- A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis — Completed
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) — Status unconfirmed
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
- Imaging of Coronary Plaques in Participants Treated With Evolocumab — Completed
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
- TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) — Stopped early
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
- Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial — Stopped early
- The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early